Ronavax Roulette — No Cure, No Control: The Risks of Genetic Vaccines

By Julie Beal

The coronavirus vaccines could cause serious illness for which there is no cure, and they could cause weird mutations in the natural world which we cannot control. As well as cancer and auto-immune problems, there’s a lot that could go wrong, as a result of genetic changes brought about by the lab-made sequences in the vaccines. Doctors and other health professionals won’t understand and won’t be able to help because the changes cannot be undone.

Each injection will be credited to a health-pass app on your phone and linked to your unique global identity, which you could need just to leave the house by the time the vax are ready in a year or two. The risks boil down to your own individual set of genes, your level of health, and the vaccine in question. But it’ll probably be a genetic vaccine, with powerful, equally unlicensed, additives, because those are the ones that’ll be ready first, and they’re already mostly paid for.

This article will explain the basic types, and outline the risks, to help you make an informed choice. It will examine what the experts themselves say about genetic vaccines, and what has already gone wrong in tests on humans. It’ll also take a brief look at some of the new adjuvants being added to the ronavax, but there’s so much to say, there will be two extra articles to cover it properly!

The three main vectors

A vector is what’s used to contain the fake genes and get them INSIDE YOUR CELLS. The three main types are: i) synthetic viruses, as used by J&J and AstraZeneca; ii) lipid nanoparticles, as used by Pfizer, Curevac and Moderna for their mRNA ronavax, and, iii) bacterial plasmids supplemented with electrical stimulation (electroporation), as used by Inovio. Different vectors have different risks, as well as the other stuff that’s added. It’s also a question of just how new they are, because there is a lot of information about the use of viral and plasmid vectors, but very little about mRNA. And in terms of the additives (adjuvants), most of them haven’t been licensed before, so information on those is also limited. However, lipid nanoparticles have been used for over a decade, and they don’t have a good track record. This is why it all gets a bit complicated, but don’t let that put you off…. just picture Bill Gates’ smiling face and remember the reset cabal are relying on everyone being bamboozled!

VIRUSES AND PLASMIDS AS VECTORS FOR GENES

Although adenoviruses are popular as vectors for gene delivery, lots of other viruses are used too. Some being used for ronavax include measles, rabies and parainfluenza viruses. Early clinical trials using adenoviral vectors had to be scrapped, “because of acute inflammatory responses and toxicity”:

“…. Since Edward Tatum’s initial proposal to repurpose viruses for therapeutic gene delivery in 1966 …. gene therapy has experienced a few undesired clinical outcomes due to off-target effects, cytotoxicity, viral transmissibility, impurity, and an immune response to the viral vector itself.”

“Because it often uses repurposed viruses to deliver therapeutic genes, gene therapy has been caught in a vicious cycle …. owing to immune response, insertional mutagenesis, viral tropism, off-target activity, unwanted clinical outcomes (ranging from illness to death of participants in clinical trials), and patchy regulations.”

A virus is a tiny piece of genetic code, smaller than bacteria. It’s not alive, so it doesn’t reproduce.; instead, it replicates inside cells. The synthetic chimpanzee adenoviruses described above are designed to be ‘non-replicating’, although the FDA advises the gene therapy industry to monitor adenoviruses in cell substrates during production to see if some of them are becoming replication competent “as a result of recombination between the vector genome and the cellular genome.”

Another potential problem with viral vectors is they could undergo changes which make them revert back to their original ‘virulent’ form. “An example of virulence reversion was documented with the use of recombinant vaccinia–rabies glycoprotein virus vaccine prepared for wild raccoons and foxes. A 28-yr-old pregnant woman was infected with this live, recombinant rabies–vaccinia virus when it contacted her open wound.”

With both adenoviruses and bacterial plasmids, there is a risk of integration of vaccine DNA in the host genome. And according to the WHO, “Bacterial DNA can promote the production of IgG anti-DNA auto-antibodies”, which is associated with the development of auto-immune diseases such as lupus. An article published in Nature said the adenovirus may cause, “a significant number of cells [to] acquire genome-integrated vector fragments” and that DNA plasmids could also cause “the integration of vector sequences into the host-cell genome”.

Gene Transfer

The World Health Organisation also warns that bits of foreign DNA can find their way into the vaccine during production: “Theoretically, the introduction of extraneous DNA …. could cause a transformation event leading to the formation of tumour cells”.

Synthetic genes could become inserted into your genome, or into the micro-organisms that live inside you, leading to mutations. Alternatively, you might have a genetic susceptibility to one or more diseases, which could be triggered by a ‘ronavax’. For instance, as noted by the FDA, antibiotic resistance genes could be transferred by the vaccines, as can happen after eating GM food. All of the genetic vaccines are a pick ‘n’ mix assortment of genetics. J&J’s ronavax, for example, uses a bacterial plasmid to create an adenovirus, into which they insert a ‘transgene expression cassette’. Everything gets messed around with – the adenovirus genome has bits removed and replaced, e.g. with “codon-optimized SARS-COV-2 Spike genes”, combined with “the human cytomegalovirus promoter and the SV-40 polyadenylation sequence”. This concoction is ‘expressed’ in human cells (called PER.C6), obtained from an aborted human foetus.

Contamination

“Every person, reagent, and piece of equipment in the laboratory is a potential vehicle for invasive microbes, unwelcome cells and chemical impurities ….. pathogens carried by cells (either intentionally or accidentally) or in components of the culture medium are potential health hazards, and laboratory-acquired viral infections have been reported.” It is even possible for some organisms to get into vaccines without being detected. This happened in a recent gen-vax trial for HIV – the vaccine was eventually found to be contaminated with mycobacteria. In fact, “it is estimated that 5 – 30% of all cell cultures today are contaminated with mycoplasma species alone. Incidence of viral contamination of common cell lines exceeded 25% in one study, and non-cytopathic viruses are even more likely than mycoplasma to escape detection, as culture health may not provide clues to their presence.”

And who knows what could go wrong during production? This is such a new industry, and it lacks manufacturing experience and the right kind of staff – so how will they find qualified technicians, and who will provide oversight?

Additives

This is where things start to get even murkier … it takes us into the realm of genetics again, because now some additives are just genetic code. And some of them mess around with DNA so much that they stray into the world of XNA, a reinvented version of DNA never seen in nature … which is a different proposition altogether when it comes to putting something inside your cells!

Adjuvants are substances designed to aggravate the immune system into reacting more. Some of the ronavax contain alum, which has been used in conventional vaccines for decades, and linked to many side effects. But the main genetic ronavax contain a range of novel substances for people to contend with, any of which could cause adverse side effects. Some of them are encoded with molecular adjuvants, i.e. they contain signalling molecules such as “cytokines, chemokines, immune costimulatory molecules, toll-like receptor agonists or inhibitors of immune suppressive pathways. New approaches including gene knockdown, epigenetics and systems biology have also contributed to an increased range of molecular adjuvant options.” Patents include long lists of additives you wouldn’t dream of, such as cholera toxin, protamine, flagellin, and human genes.

Even the vector can be an adjuvant: bacterial plasmids and lipid nanoparticles, used to contain mRNA stimulate the immune system into reacting. As mentioned above, lipid nanoparticles have already been used as an adjuvant in several vaccines, and were linked to hundreds of young people developing narcolepsy after getting the Pandemrix vaccine in 2009. (This will be covered more in a separate article.)

Electroporation (EP) involves passing an electric current through the tissue, straight after injection of a DNA plasmid vax. It’s needed to break down the cell walls so the plasmid can get in, but can lead to cell death (i.e. irreversible EP). It can induce muscle contractions, and damage the skin and tissue, and is said to work as an adjuvant.

DNA uses adenine, thymine, guanine, and cytosine, while RNA uses uracil instead of thymine. However, producing genetic code is neither simple nor ‘clean’. The process of making it useable is long and complicated, requiring various reagents, heat, etc. Cell lines used to produce recombinant vaccines require a broth to feed and maintain them, and can require up to fifty ingredients, such as “growth factors, amino acids, reducing agents, or vitamins.” Some gen-vax use foetal cells from aborted babies (HEK-293, and J&J’s PER.C6), HeLa cells (immortal cancer cells from a woman’s cervix) and Vero cells (from a monkey’s kidney).

Gen-vax using mRNA are said to avoid use of these cells, but to make mRNA, a bacterial plasmid is used to transcribe the mRNA from DNA . Curevac, who are also making a ronavax, describe this process in their patent for a MERS coronavirus vaccine. Plasmid DNA constructs were transformed and propagated in E. coli bacteria, and used an E. coli gene and a polymerase from a bacteriophage.

What about the microchip?

There’s no point putting a microchip or metallic nanoparticles in the vaccine because it’s not possible to control where they end up. They would get lodged in body tissues and be mostly unreadable. An RFID chip needs to be implanted just under the skin, using a special needle. Besides, they only work on things up close, so they’re not much use. Smartphones, on the other hand, have a unique ID, GPS tracking, accelerometer, gyroscope, biometrics, apps, and ‘rechargability’. You look after your own slavery device. Once the global ID system is established, in line with the blockchain and digital Global Credits, more people will choose to pop a tag in their hand to link with their ID-protected smart devices. Some people might wear a wristlet to measure galvanic skin response for extra credits. Both the microchip and the wristlet could be used for geo-fencing or people separation purposes.

Gene editing techniques are in the early stages of development, and very expensive, whilst sterilization has to target the cells involved in reproduction. Vaccines containing gonadotropin don’t seem to create lasting contraception, although research published in 2018 reports that a DNA vaccine led to “suppression of testosterone and impaired fertility in immunized mice”. No matter what’s in the ronavax, though, they mean risking your health and signing up for slavery. Because the two are planned to go hand-in-hand – you’d need both the vaccine and the app just to venture outside of your house, and avoid the isolation camps.

Ronavax trials

There have already been two cases of an MS-like disease called transverse myelitis reported in AstraZeneca’s ronavax trials. Did something in the vaccine trigger a genetic predisposition in these individuals? Johnson and Johnson use the adenovirus in their ronavax, too, and also halted the trial when someone had a sufficiently adverse reaction, but both companies are soon to resume the trials.

“In the Johnson & Johnson trial, which was paused on Oct. 12, a man who received a vaccination suffered a stroke that may have been triggered by an infection. To conclude it was not likely to be related to the shot, investigators probed not only the medical details of the event, but also examined a safety database of 100,000 people who have received vaccines that use the same underlying technology. The investigation found “no clear cause” of the incident, according to a company statement. It also found no evidence the vaccine triggered the event, the details of which were not disclosed by the company.” Similarly, J&J said that although “no clear cause has been identified”, they had “found no evidence that the vaccine candidate caused the event.” Having ‘no clear cause’ does not rule out the possibility it was connected to the vaccine. Viruses and bacteria affect each other so what infection did the person have? The interplay between organisms can affect whether or not you end up getting ill when pathogens compete inside you, so it deserves much more investigation. The reliance on data from people who’ve had similar vax is also a concern – did they have the same vaccines? Or the same vectors, adjuvants, and dose? Have any long term studies on the genetic effects of such vaccines ever been done?

Previous trials of gen-vax

One of the selling points of gen-vax is that they are ‘plug-and-play’ platform vaccines, which can be manufactured very quickly. So if a pandemic occurred, a new genetic sequence could be knocked up in no time on a computer, popped in an ‘expression cassette’, and used in place of whatever is currently being produced. So, as long as the factory lines are rolling, with whatever platform is being used, Big BioPharma can come to the rescue. There have been a lot of trials of genetic vaccines already, so it helps to see what happened in those.

For instance, a tuberculosis vaccine using the same ChAdOx1 vector that’s in AstraZeneca’s ronavax, was trialled in 42 healthy UK adults. There were four severe systemic AEs (e.g. fatigue, feverishness and headache) and 14 haematological AEs (i.e. blood abnormalities) which were all deemed related, e.g. lymphopaenia, neutropaenia, and leukopaenia. One person reported transient axillary lymphadenopathy (changes in lymph nodes); another person “had a moderate lymphopaenia … which was ongoing at the end of the study”, i.e. they hadn’t got better.

Parexel and Moderna trialled the H10N8 flu vaccine (mRNA-1440) which found that of the 145 people dosed, there were 124 unsolicited AEs, including upper respiratory tract infection, back pain, pharyngitis, and oropharyngeal pain. There were also five severe AEs (erythema, headache, back pain, tonsillitis, and ruptured ovarian cyst) and two serious AEs, cholecystitis (inflammation of the gallbladder) and ruptured ovarian cyst (it’s not clear if this happened to one person twice, or to two people). Most of these AEs were deemed unrelated to mRNA-1440.

Another Moderna vaccine, this time for Human Metapneumovirus and Parainfluenza Virus 3 (mRNA-1653), was trialled in Texas and Nebraska. There were ten medically attended events in a group of just 94 people, none of which were ‘solicited’ symptoms.

Moderna advise that their vaccine platform, “may induce immune reactions from either the mRNA or the lipid as well as adverse reactions within liver pathways or degradation of the mRNA or the LNP, any of which could lead to significant adverse events in one or more of our clinical trials. Many of these types of side effects have been seen for legacy LNPs.” Moderna is currently trialling a Zika vaccine on babies, beginning when they are 29 days old.

Early gene therapy trials

Use of an adenovirus in a gene therapy trial in 1999 led to the death of a young man called Jesse Gelsinger, just four days after the injection. He was only 18, and he wasn’t told that two lab monkeys had already died, and previous volunteers also had adverse reactions. Afterwards, “the FDA and NIH revealed that 691 volunteers in gene-therapy experiments had either died or fallen ill in the seven years before Jesse’s death; only 39 of these incidents had been reported promptly as required.”

Use of gamma retroviruses as vectors led to, “cases of leukaemia after X-SCID gene therapy and the …. deaths of some patients following gene therapy against Wiskott–Aldrich syndrome”. Another patient, Jolee Mohr, aged 36 and suffering from rheumatoid arthritis, was injected with an adeno-associated vector; she “experienced vomiting and fever soon after the second injection”, and died three weeks later. This was deemed unrelated and the trial restarted.

The Parexel/TeGenero trial of TGN1412 involved administering monoclonal antibodies from a humanized mouse. All six men who received a dose had “the same kind of ‘cytokine storm’ that had killed Jesse Gelsinger. Their heads and bodies grotesquely swollen, they were rushed into intensive care.” They never fully recovered and are “considered to remain at high risk of cancer and immune-system disturbances”. This trial also highlights another problem with gen-vax: animal models aren’t much use. Their genetics are different to ours. An inquiry into what went wrong found that tests on animals hadn’t helped them to figure out the right dose to use. Humans are not like macaques, it turns out. Sometimes we’re more like chimpanzees, leading to “differences in T cell activation and cytokine release”, for example.

The thing about the gen-vax trials that have taken place in the past is that they have been judged in the same way as traditional vaccines and drugs. Despite the WHO commenting that, “Classical safety or toxicological testing, as recommended for chemical drugs, will have limited application to a plasmid DNA product”, the trials have not been adjusted accordingly. There seem to be no long term follow-ups, no checks on genetic effects, no apparent oversight, and no apparent regard for the potential effects on other people, or the environment.

Nonetheless, key players in the global reset, including the World Bank, United Nations, World Economic Forum, and nation states, are pushing very hard for us to accept the coronavirus vaccines. At the start of 2020, there were a lot of failed genetic vaccines and no licenses, so can we really be expected to roll up our sleeves and get the app in blind faith?

An easy-to-catch global infection like the rona is just what was needed to get these things up and running, because, to get licensed, they need lots of healthy people to take part in trials, and a virus that’s everywhere so they can use their slick tests to ‘prove’ the vaccine works. Up until this year, all they had was very sick people with cancer, etc., and a handful of trials, mainly in countries where they have diseases like Ebola and malaria. In January, it was said the FDA expected to receive 200 applications in 2020 for gene therapy products, and to approve up to twenty products a year by 2025, but there was still “no way to reliably scale up production”, and even the largest facilities built by Gilead and Novartis could only produce a few hundred doses per year. This made gene therapy too expensive. Now, however, production capacity is booming globally.

Regular vaccination of the masses means the rich can get personalised treatments and blood plasma products. Team Reset sees you as a piece of meat, and they want every pound of flesh accounted for. Life on the farm means behaving as required and keeping fit, to keep the system ‘balanced’ for the circular economy. The ronavax are just to get the ball rolling – synthetic genetic monstrosities and the patenting of everything you once knew and loved are but one step away. All that’s needed now is a quick side-step of the Nagoya and Cartagena Protocols as the WHO subsumes the CBD.

See Part 1: We Need to Talk About Proteins — The Ronascam, The Vaccines, and Genetic Patents

See Part 2: Ronavax Rundown

See Part 3: A Guide to the Ronavax — Understanding the Experimental Coronavirus Vaccines

Image: Pixabay

Become a Patron!

Subscribe to Activist Post for truth, peace, and freedom news. Send resources to the front lines of peace and freedom HERE! Follow us on SoMee, HIVE, Parler, Flote, Minds, and Twitter.

Provide, Protect and Profit from what’s coming! Get a free issue of Counter Markets today.